Literature DB >> 31324299

Editorial on: Eculizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder.

Santiago Pardo, Gavin Giovannoni, Christopher Hawkes, Jeannette Lechner-Scott, Emmanuelle Waubant, Michael Levy.   

Abstract

Entities:  

Keywords:  Complement; Disease-modifying therapy; Eculizumab; NMO; NMOSD; Neuromyelitis optica spectrum disorder

Year:  2019        PMID： 31324299     DOI： 10.1016/j.msard.2019.07.001

Source DB:  PubMed          Journal:  Mult Scler Relat Disord        ISSN： 2211-0348            Impact factor:   4.339


× No keyword cloud information.
  5 in total

1.  Validation of claims-based diagnoses of adult and pediatric neuromyelitis optica spectrum disorder and variations in diagnostic evaluation and treatment initiation.

Authors:  Sabrina Gmuca; Duriel I Hardy; Sona Narula; Sharon Stoll; Julia Harris; Yongdong Zhao; Rui Xiao; Pamela F Weiss; Amy T Waldman; Jeffrey S Gerber
Journal:  Mult Scler Relat Disord       Date:  2019-11-01       Impact factor: 4.339

Review 2.  Differential Effects of MS Therapeutics on B Cells-Implications for Their Use and Failure in AQP4-Positive NMOSD Patients.

Authors:  Jan Traub; Silke Häusser-Kinzel; Martin S Weber
Journal:  Int J Mol Sci       Date:  2020-07-16       Impact factor: 5.923

Review 3.  Treatment and Relapse Prevention of Typical and Atypical Optic Neuritis.

Authors:  George Saitakis; Bart K Chwalisz
Journal:  Int J Mol Sci       Date:  2022-08-29       Impact factor: 6.208

Review 4.  Neuromyelitis Optica Spectrum Disorder Treatment-Current and Future Prospects.

Authors:  Marta Waliszewska-Prosół; Justyna Chojdak-Łukasiewicz; Sławomir Budrewicz; Anna Pokryszko-Dragan
Journal:  Int J Mol Sci       Date:  2021-03-10       Impact factor: 5.923

Review 5.  Recent progress in maintenance treatment of neuromyelitis optica spectrum disorder.

Authors:  Trygve Holmøy; Rune Alexander Høglund; Zsolt Illes; Kjell-Morten Myhr; Øivind Torkildsen
Journal:  J Neurol       Date:  2020-10-03       Impact factor: 6.682
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.